The global pandemic has forever changed how patients, sites staff, sponsors, CROs and vendors engage in clinical research. With hundreds to thousands of trials working towards treatments and preventions for the virus, it’s necessary that trials evolve to fit into our world’s new limitations. These changes can be positive for the industry, but everything rests on the ability to adapt.
So, how should we think about our “new normal?”
In episode six of The Latest Dose, our host Kathy Vandebelt discusses how to get comfortable with the use of mobile technologies in clinical trials with our guest, Jennifer GoldSack. Jen serves as the Executive Director of the Digital Medicine Society (DiMe). Jen was also an Olympic athlete, and ties in her experience in the Olympics with the topic at hand – biometric monitoring.
But what is biometric monitoring and how can we embrace it in clinical trials? What’s the difference between consumer wearables and biometric technology?
In this discussion, Jen talks about the differences between consumer wearables and technology appropriate for biometric monitoring, how to embrace digital measurement in clinical research, and about DiMe’s V3 framework – the foundation to determine fit-for-purpose for biometric monitoring technologies. You’ll also hear more about where biometric monitoring is playing a part in athletics, as well as more about her experience as an Olympian in the pre-wearable era.
Tune into our podcast below and visit The Latest Dose to listen to our other five episodes. Remember to subscribe and look out for our upcoming podcast next month.
If you’re interested in biometric monitoring technology and learning more about DiMe’s V3 framework, here are some resources to help you get started:
If you’d like to learn more about the Digital Medicine Society and join its community, please visit dimesociety.org.